Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),General Medicine
Reference33 articles.
1. Brown MG, Kirby S, Skedgel C, Fisk JD, Murray TJ, Bhan V, et al. How effective are disease-modifying drugs in delaying progression in relapsing-onset MS? Neurology. 2007;69:1498–507.
2. Yamout BI, Alroughani R. Multiple sclerosis. Semin Neurol. 2018;38:212–25.
https://doi.org/10.1055/s-0038-1649502
.
3. Happe LE. Choosing the best treatment for multiple sclerosis: comparative effectiveness, safety, and other factors involved in disease-modifying therapy choice. Am J Manag Care. 2013;19:s332–42.
4. Le Page E, Edan G. Induction or escalation therapy for patients with multiple sclerosis? Rev Neurol (Paris). 2018;174:449–57.
https://doi.org/10.1016/j.neurol.2018.04.004
.
5. Singer BA. The role of natalizumab in the treatment of multiple sclerosis: benefits and risks. Ther Adv Neurol Disord. 2017;10:327–36.
https://doi.org/10.1177/1756285617716002
.
Cited by
21 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献